ADL Amdl,

TUSTIN, Calif., Aug. 14 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), an international biopharma company headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., announced today that for the three-month period ended June 30, 2007, the Company expects to report revenues of $2,459,535 (unaudited), an approximate 79 percent increase over the first quarter. The Company also has filed a Form 12b-25 with the Securities & Exchange Commission indicating that its Form 10-QSB for the six months ended June 30, 2007, would not be filed by August 14, 2007. AMDL said it expects to file the required report by August 20, 2007, in the time allotted by the rules so as to maintain its '34 Act compliance. Gary Dreher, President, said, "We are delighted with AMDL's sales growth and look forward to robust third and fourth quarter results. Accounting for our operations in China is challenging and we need the additional time to properly prepare the Form 10-QSB." About AMDL: AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, Investor Relations for AMDL, Inc., +1-949-707-5365, voice mail, +1-714-505-4460 Web site: http://www.amdl.com/

Copyright